Pharma / Medical
Pure Health Products aims to make people naturally healthy and promote a better world. Pure Health Food Products are formulated from a select composition of organically grown grains, vegetables, herbs and spices. Our composition and processing techniques are aimed at achieving maximum potency with no side effects.The products are free from chemicals, artificial coloring, additives, artificial flavoring and preservatives.
There is a large variety of products for you and your family and while our products may have the therapeutic and nutritive value for a weakened body, their primary function is for your total wellness hence helping you take control of your health and wellness destiny. Sometimes it seems that nothing is safe to eat, and that we live in constant state of food anxiety, but you must not feel helpless.There is plenty of safe food, delicious food to eat. And for your well-being, Pure Health Products are now available for your wellness.
We provide re-birth of wellness by creating awareness on healthy living and providing high quality, healthy and tasty food products across East Africa.
verified
NAIROBI
Pharma / Medical
Company Profile PokuPharma is a limited liability company registered under the companies code 1963 (Act 179). Having complied with the provisions of companies' code, it commenced business in 5th march 1998 to supply pharmaceutical products under the pharmacy act 1994(Act 489) section 30 and 31. The company is located at Kumasi Asafo near Ahmadiah mosque in the Ashanti Region of Ghana West Africa. Objectives The objectives of PokuPharma are to supply quality drugs and ensure quality healthcare throughout the country. In the future PokuPharma entry in the pharmaceutical industry can best be described as the dawn of the new dimension in the pharmaceutical distribution channel. As the holders of the largest distribution network we ensure that a product from us reaches every corner of the country. The future of the company is bright and the possibility of producing our own drug and affiliation with international pharmaceutical companies has not been left out in the quest for bigger growth.
verified
KUMASI
Pharma / Medical
Laboratory & Allied was incepted in 1968 and incorporated in November 1970 under the Company Act as a private trading company dealing mainly in general healthcare sundries and toiletries, laboratory chemicals and glassware, and other related products.
As a family-owned company under the able management of the founder Mr. Vithal Patel, the company diversified into pharmaceutical wholesaling in 1971, where it became the front-runner in the supply of basic essential drugs to the govemment administered public health sector and comprehensive drugs supplies to the private sector in the entire tropical regions of East, Central, and Southem Africa. L&A took calculated advantage of the government policy of supporting local entrepreneurs in the pharmaceutical sector, to increase manufacturing capacity and capability, by investing heavily in pharmaceutical manufacturing.
L&A grew to become one of the leading suppliers of quality-approved pharmaceutical products to the government's Essential Drugs Programme. (EDP) Due to the increasing health-care demands in Kenya and the region, the modest manufacturing facility along Enterprise Road in the Industrial Area of Nairobi was soon outstripped in through-put capacity.
Thus, a modern spacious and custom designed GMP-certified facility was inaugurated mid-1990 along Mombasa Road; the present location of L&A. From this facility L&A produces all kinds of formulations, including sterile injectables, liquid suspensions and syrups (both large and small volume), solid dosage forms (tablets and capsules), aerosols, inhaler aerosols, dry-powder filling as well as creams and ointments, impregnated sterile gauze, dental cartridges and roll-on medication. The entire facility and layout is well segregated with an independent penicillin plant having dedicated air-flow and fluid ducting systems.
Today, L&A continues to build on its equity rating as one of Africa's leading pharmaceutical manufacturers by developing a comprehensive range of products and formulations and investing in products formulations research.
"Our commitment to healthcare is reflected in the continuing development of new products and dosage forms aimed at effectively meeting the health needs of the people" says Managing Director Manesh Patel "In formulating our products we not only are cognizant of the treatment regime but also of the socio-economic impact our products impart towards the general welfare of the people".
L&A today has in its portfolio over 150 product presentations covering all areas of healthcare ranging from:
Ethical (prescription) pharmaceutical products
Over-the-Counter (OTC) medicines
Fast moving general pharmaceutical and healthcare products.
Animal Healthcare" and Veterinary products.
Because of its earlier involvement in the EDP, L&A continues to hold premier position as the leading supplier of drugs and medicines to the government, quasi-government institutions and Non-Governmental Organisations (NGO's) having in its portfolio products for virtually every therapeutic and clinical indication.
Through its high rating performance and consistency in the manufacture and delivery of the pioneer Drugs Kits to the MoH and donor supported health delivery programs spanning over 20 years, L&A is today rightly considered the leading supplier to the MoH Essential Drugs Kits system in particular, and the preferred supplier to the public healthcare system, in general.
verified
NAIROBI
Pharma / Medical
Pharm Access Africa Limited (PAAL) is a healthcare organization linking private sector initiative to those of donor organizations to enhance healthcare to communities. PAAL was set up in early 2001 with the object of increasing access to healthcare in the Anglophone and Francophone countries of Eastern and Central Africa. In 2001, health expenditure per capita in Kenya was US$29. The figure was US$14 for Uganda, US$12 for Tanzania and US$3 for Ethiopia compared to the global figure of US$500.
Access to healthcare is very limited - with over 50 per cent of populations having no access to healthcare whatsoever. With close to 65 percent of those living with HIV/AIDS in sub-Saharan Africa and all of them being in the most active and economically productive years of their lives, HIV/AIDS will put further pressure on these impoverished economies.
All the health sector and economic gains have been eroded in the last decade. According to a report presented to the British Parliamentarians and The Royal African Society on May 20th 2004, 'The disease depresses sub-Saharan GDP rate by 0.8 percentage points. In the worst hit countries, where more than one-fifth of the adults have HIV, the burden is 2.6 points'. PAAL started off with offering consultancy services on accelerated access programs to one of the largest pharmaceutical companies and their associates in Kenya, Uganda, Rwanda, Burundi, Ethiopia, Tanzania, Zambia and Zimbabwe. Sales and Marketing consultancies along with assistance in regulatory affairs are offered to a number of local and to some international companies. Pharm Access Africa Limited supports DART study on anti-retroviral therapy at The Joint Clinical Resaerch Centre in Kampala, Virus Research Institute, Entebbe and The University of Zimbabwe, Harare.
This is in collaboration with The Imperial College London and The Medical Research Council of Great Britain. Pharm Access Africa Limited works closely with the Kenya Association of Manufacturers, HIV-AIDS Business Council, African Medical Research Foundation, Global Health International, National Organization of Peer Educators, Touch Africa- Michael Kijana Wamalwa Foundation, National Museums of Kenya and I Choose Life.
Healthcare in Africa
As a (semi-) public good, healthcare requires large government intervention. However, many African countries suffer from limited state capabilities and poor institutions. As a result, many people turn to the private sector and, since insurance is not available for most, pay for healthcare out-of-pocket.
Despite its important role, the private sector is often weakly regulated and highly fragmented. Due to the high investment risk it has limited or no access to the capital required for quality improvement and expansion of its services. And low quality in the clinics means low trust among patients. Another reason for few insured patients. The high proportion of out-of-pocket spending and the lack of trust in healthcare provision leads to low and unpredictable income for healthcare providers. This limits their options for investing in the quality, scope and scale of their services even further.
verified
NAIROBI
